Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol
January 2025
GOG Foundation, Florida Cancer Specialists and Research Institute, West Palm Beach, FL 33401, United States of America. Electronic address:
Objective: Therapeutic interventions for epithelial ovarian cancer (EOC) have increased greatly over the last decade but improvements outside of biomarker selected therapies have been limited. There remains a pressing need for more effective treatment options that can prolong survival and enhance the quality of life of patients with EOC. In contrast to the significant benefits of immunotherapy with immune checkpoint inhibitors (CPI) seen in many solid tumors, initial experience in EOC suggests limited efficacy of CPIs monotherapy.
View Article and Find Full Text PDFEfficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study.
Lancet Reg Health Eur
February 2025
Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, Berlin, 13353, Germany.
Article Synopsis
- The study investigates the effectiveness of immunoadsorption (IA) treatment on post-COVID myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) patients, focusing on those with elevated β2 adrenergic autoantibodies.
- Patients underwent five IA sessions and showed significant improvement in physical functioning, fatigue, and other symptoms over six months, with 70% responding positively to the treatment.
- The findings suggest that IA could be a beneficial therapy for alleviating symptoms in post-COVID ME/CFS patients, indicating a possible link between autoimmunity and the condition.
Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration.
Eur Respir J
December 2024
Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Background: Exercise pulmonary hypertension (PH) was defined by a mean pulmonary arterial pressure (mPAP)/cardiac output (CO) slope >3 mmHg·min·L between rest and exercise in the 2022 European Society of Cardiology/European Respiratory Society PH guidelines. However, large, multicentre studies on the prognostic relevance of exercise haemodynamics and its added value to resting haemodynamics are missing.
Patients And Methods: The PEX-NET (Pulmonary Haemodynamics during Exercise Network) registry enrolled patients who underwent clinically indicated right heart catheterisations both at rest and ergometer exercise from 23 PH centres worldwide.
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer.
J Exp Med
January 2025
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Despite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors that initially responded but eventually developed AR to anti-PD-1, alone or in combination with anti-CTLA-4. Resistant tumors harbored decreased infiltrating T cells and reduced cancer cell-intrinsic MHC-I and MHC-II levels, yet remained responsive to IFNγ.
View Article and Find Full Text PDFAssociation of Lipoprotein(a) With Changes in Coronary Atherosclerosis in Patients Treated With Alirocumab.
Circ Cardiovasc Imaging
November 2024
Department of Cardiology, Bern University Hospital, Inselspital (K.C.K., J.H., Y.U., T.O., H.S., R.K., F.P., M.A., J. Lanz, S.W., L.R.), University of Bern, Switzerland.
Background: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy.
Methods: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!